On Thursday shares of Avon Products Inc. (NYSE:AVP) closed at $8.80. Company’s sales growth for last 5 years was -2.80% and EPS growth for next 5 years is recorded as 3.80%. On 14 April, Avon Products Inc. (NYSE:AVP) said that, it is exploring a sale of its North American operations as it evaluates ways to turn around the struggling unit
58.com Inc. (NYSE:WUBA) in last trading activity increased 6.04% to close at $67.57. Company weekly performance is 24.71% while its quarterly performance stands at 67.38%. 58.com Inc. (NYSE:WUBA) is -2.41% away from its 52 week high. 58.com Inc. (NYSE:WUBA) announced that it has acquired a strategic stake in Falcon View Technology Limited (“Ganji”), the holding company of the PRC entities operating Ganji.com, a major online local services marketplace platform in China. Concurrently, 58.com also announced an approximately US$400 million additional investment by Tencent Holdings Limited (“Tencent”), a leading provider of internet services in China.
On Thursday shares of Plug Power Inc. (NASDAQ:PLUG) closed at $2.72. Company’s sales growth for last 5 years was 39.20% Equities researchers at FBR & Co. reduced their price target on shares of Plug Power Inc. (NASDAQ:PLUG) from $8.00 to $6.50 in a research report issued on Tuesday. The firm currently has an “outperform” rating on the stock. FBR & Co.’s price objective points to a potential upside of 143.45% from the stock’s previous close.
Gilead Sciences Inc. (NASDAQ:GILD) ‘s net profit margin is 48.60% and weekly performance is 2.15%. On last trading day company shares ended up $103.34. Gilead Sciences Inc. (NASDAQ:GILD) distance from 50-day simple moving average (SMA50) is 2.09%. On 7 April, Gilead Sciences Inc. (NASDAQ:GILD) announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for two doses of an investigational fixed-dose combination of emtricitabine and tenofovir alafenamide (200/10 mg and 200/25 mg) (F/TAF) for the treatment of HIV-1 infection in adults and pediatric patients age 12 years and older, in combination with other HIV antiretroviral agents.